ReviewNPJ precision oncology2023

Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.

Omar Alhalabi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.